{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:32:45Z","timestamp":1784842365030,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.090","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T07:37:05Z","timestamp":1651736225000},"page":"3633-3637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Covid-19 vaccine immunogenicity in people living with HIV-1"],"prefix":"10.1016","volume":"40","author":[{"given":"Lauriane","family":"Nault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorie","family":"Marchitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Goyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tremblay-Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Martel-Laferri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.vaccine.2022.04.090_b0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.090_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10269","key":"10.1016\/j.vaccine.2022.04.090_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.090_b0020","doi-asserted-by":"crossref","first-page":"1699.e5","DOI":"10.1016\/j.cmi.2021.06.043","article-title":"Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in health care workers: an observational study using surveillance data","volume":"27","author":"Paris","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.090_b0025","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2022.04.090_b0030","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.vaccine.2022.04.090_b0035","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.090_b0040","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/ajt.16607","article-title":"Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients","volume":"21","author":"Marinaki","year":"2021","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.090_b0045","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1111\/ajt.16710","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.090_b0050","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.090_b0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.090_b0060","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.vaccine.2022.04.090_b0065","article-title":"Antibody Response to COVID-19 vaccination in Patients Receiving Dialysis","author":"Anand","year":"2021","journal-title":"medRxiv"},{"issue":"22","key":"10.1016\/j.vaccine.2022.04.090_b0070","doi-asserted-by":"crossref","first-page":"E793","DOI":"10.1503\/cmaj.210673","article-title":"Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis","volume":"193","author":"Goupil","year":"2021","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2022.04.090_b0075","article-title":"The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.090_b0080","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3018(21)00099-0","article-title":"Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV","volume":"8","author":"Touizer","year":"2021","journal-title":"Lancet HIV"},{"issue":"14","key":"10.1016\/j.vaccine.2022.04.090_b0085","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/QAD.0000000000003017","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV","volume":"35","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2022.04.090_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.090_b0095","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.090_b0100","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02590-20","article-title":"Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals","volume":"11","author":"Beaudoin-Bussi\u00e8res","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2022.04.090_b0105","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","author":"Anand","year":"2021","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.090_b0110","doi-asserted-by":"crossref","first-page":"108790","DOI":"10.1016\/j.celrep.2021.108790","article-title":"Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2","volume":"34","author":"Gasser","year":"2021","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.090_b0115","doi-asserted-by":"crossref","first-page":"100126","DOI":"10.1016\/j.xcrm.2020.100126","article-title":"Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike","volume":"1","author":"Pr\u00e9vost","year":"2020","journal-title":"Cell Rep Med"},{"issue":"1137\u201350","key":"10.1016\/j.vaccine.2022.04.090_b0120","article-title":"A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses","volume":"29","author":"Tauzin","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6541","key":"10.1016\/j.vaccine.2022.04.090_b0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.abf2303","article-title":"Structural impact on SARS-CoV-2 spike protein by D614G substitution","volume":"372","author":"Zhang","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.090_b0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"issue":"7871","key":"10.1016\/j.vaccine.2022.04.090_b0135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.090_b0140","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41590-019-0418-x","article-title":"Altered differentiation is central to HIV-specific CD4(+) T cell dysfunction in progressive disease","volume":"20","author":"Morou","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2022.04.090_b0145","doi-asserted-by":"crossref","first-page":"102727","DOI":"10.1016\/j.ebiom.2020.102727","article-title":"Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy","volume":"54","author":"Niessl","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:02Z","timestamp":1759403702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005436"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.090","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.13.456258","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covid-19 vaccine immunogenicity in people living with HIV-1","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}